– USA, CA – Rondo Therapeutics, a privately-held biopharmaceutical company advancing next-generation immuno-oncology platforms, announced the appointment of Steve James to its Board of Directors, bringing over three decades of biopharmaceutical experience to the Board.
“We are thrilled to welcome Steve to the Board. With Steve’s business acumen and transactional experience, our board and leadership team are uniquely positioned to deliver transformative solid tumor therapies to patients,” said co-founder and CEO, Shelley Force Aldred.
About Steven James
Steve James was instrumental in building and leading several companies into the clinic, resulting in $2B+ in M&A value for stakeholders. His addition to the Board of Directors strengthens Rondo’s leadership team as the company continues to drive the development of T-cell-engaging bispecific antibodies for solid tumors.
“There is great therapeutic potential for bispecific antibodies to address significant unmet needs in solid tumors. I am impressed by what the team at Rondo Therapeutics has accomplished to date, and I am excited to be a part of Rondo’s continued growth,” said Steve James.
Steve James comes to Rondo with a proven record of building companies in the biotech industry. Most recently he was President and CEO of Pionyr Immunotherapeutics. Under his leadership the company made significant therapeutic advances in novel target discovery and antibody generation, targeting immunosuppressive cells in the tumor microenvironment. The company was acquired in parts by Gilead and Ikena Oncology. Before Pionyr, Steve James served as president and CEO of Labrys Biologics, leading its acquisition by Teva Pharmaceuticals. Before Labrys, Mr. James was president and CEO of KAI Pharmaceuticals which was acquired by Amgen. Mr. James also serves on the boards of Juneva Therapeutics, Lyterian Therapeutics, Ventus Therapeutics, and Allakos, Inc.
Steve James has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and Eli Lilly. He received his MBA from Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University.
About Rondo Therapeutics
Rondo Therapeutics is a biopharmaceutical company exploring new frontiers in cancer therapy. Rondo Therapeutics’ mission is to advance bispecific antibody therapies, specifically targeting unmet needs in solid tumors. Our solution is to create a new class of bispecific antibodies that harness the immune system’s power to target and eliminate tumors safely.
For more: https://www.rondotx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.